GSK will pay $90 million to settle diabetes drug allegations

Share this article:
GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). As a result of the settlement, GSK must change the way it promotes its diabetes drugs, including Avandia. However, the company did not admit to “any wrongdoing or liability of any kind.” The states charged that GSK did not report some Avandia safety data. They also said the drug manufacturer violated consumer protection laws when it misrepresented heart attack risk with the drug, as well as the safety of its use, alone or in combination with other drugs.

Share this article:

More in Products

LeadingAge's CAST releases EHR matrix selection tool

LeadingAge's Center for Aging Services Technologies released its 2014 version of a tool to let long-term providers choose the best electronic health record for their facility.

New magnetic badges debut

New magnetic badges debut

Imprint Plus has introduced The Mighty Badge name badge kit, which allows users to create reusable but personalized badges.

Hollister Incorporated celebrates antibacterial foam dressing

Hollister Incorporated celebrates antibacterial foam dressing ...

Hollister Incorporated's new Hydrofera Blue Ready antibacterial foam dressing has been named a "Top 10 Innovation in Podiatry" according to the Podiatry Today journal, as well as a "Top Innovation ...